שיטה פשוטה לייצור ביקושים מלאכותיים של תעודות הסל באופן שמאפשר לחברות כושלות בעלות יתרות שורט גבוהות ללחוץ על השורטיסטים ואפילו לגייס הון מניות. הכול על חשבון משקיעים תמימים בתעודות שאינם מבחינים במניפולציה.

מה אתם אומרים לקנות או לא.

MannKind is a stock that stumbled in 2015, twice! It fell to a dismal $3.60 a share in May from a February high of $7.50, recovering again in June. It once again reversed the gains to recently trade at around the $3 level, its 52-week low. Needless to say, MannKind is not for investors who abhor risk. One of the major reasons is its inhaled insulin, Afrezza, for which Sanofi (SNY - Get Report) has paid global rights to the tune of $925 million. Investors expected patients to embrace Afrezza as a welcome change to injected insulin. However, since the onset, physician and patient awareness of the insulin has been low. Some insurers are also not willing to cover the drug, only adding to company's miseries. Though there was mention that over 80% of insurers would cover Afrezza even if partially, that hasn't helped investors to date. Nor is there any convincing evidence of regulatory approvals for the drug outside the U.S.